13D Filing: Farallon Capital and Nexvet Biopharma PLC (NVET)

(ix)

The following persons, each of whom is a managing member or senior managing member, as the case may be, of both the Farallon General Partner and the Management Company and a manager or senior manager, as the case may be, of both the FCAAI General Partner and the FSSP VI General Partner, with respect to the Ordinary Shares held by the Farallon SPVs and the Ordinary Shares the Farallon SPVs have the right to acquire upon the exercise of Warrants : Philip D. Dreyfuss (“Dreyfuss“); Michael B. Fisch (“Fisch“); Richard B. Fried (“Fried“); Daniel J. Hirsch (“Hirsch“); David T. Kim (“Kim“); Monica R. Landry (“Landry“); Michael G. Linn (“Linn“); Ravi K. Paidipaty (“Paidipaty“); Rajiv A. Patel (“Patel“); Thomas G. Roberts, Jr. (“Roberts“); William Seybold (“Seybold“); Andrew J. M. Spokes (“Spokes“); John R. Warren (“Warren“); and Mark C. Wehrly (“Wehrly“).